Biohaven Pharmaceutical Holding Co Ltd (NYSE:BHVN) insider Robert Berman sold 61,314 shares of the firm’s stock in a transaction dated Thursday, June 18th. The shares were sold at an average price of $75.27, for a total transaction of $4,615,104.78. Following the completion of the transaction, the insider now directly owns 36,655 shares in the company, valued at approximately $2,759,021.85. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink.
Shares of BHVN opened at $70.04 on Thursday. The firm has a market cap of $4.31 billion, a P/E ratio of -5.55 and a beta of 1.42. Biohaven Pharmaceutical Holding Co Ltd has a 52 week low of $26.56 and a 52 week high of $76.40. The firm’s 50-day simple moving average is $59.83 and its 200 day simple moving average is $49.43.
Biohaven Pharmaceutical (NYSE:BHVN) last issued its quarterly earnings results on Thursday, May 7th. The company reported ($2.39) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($2.46) by $0.07. The firm had revenue of $1.10 million for the quarter, compared to the consensus estimate of $0.21 million. During the same period last year, the company posted ($1.41) EPS. Analysts anticipate that Biohaven Pharmaceutical Holding Co Ltd will post -9.39 earnings per share for the current year.
Institutional investors and hedge funds have recently made changes to their positions in the business. Macquarie Group Ltd. purchased a new stake in shares of Biohaven Pharmaceutical in the fourth quarter worth approximately $60,000. Sowell Financial Services LLC grew its holdings in Biohaven Pharmaceutical by 435.4% during the fourth quarter. Sowell Financial Services LLC now owns 1,285 shares of the company’s stock valued at $70,000 after purchasing an additional 1,045 shares during the period. SG Americas Securities LLC bought a new position in Biohaven Pharmaceutical during the fourth quarter valued at $122,000. Bamco Inc. NY bought a new position in Biohaven Pharmaceutical during the fourth quarter valued at $234,000. Finally, Rockefeller Capital Management L.P. bought a new position in Biohaven Pharmaceutical during the fourth quarter valued at $271,000. 97.74% of the stock is currently owned by hedge funds and other institutional investors.
BHVN has been the topic of a number of analyst reports. Cantor Fitzgerald increased their price target on Biohaven Pharmaceutical from $82.00 to $109.00 and gave the company an “overweight” rating in a research note on Tuesday. ValuEngine lowered shares of Biohaven Pharmaceutical from a “strong-buy” rating to a “buy” rating in a report on Friday, May 1st. Mizuho reissued a “buy” rating and issued a $85.00 price target (up previously from $53.00) on shares of Biohaven Pharmaceutical in a report on Tuesday, June 9th. Oppenheimer reiterated a “hold” rating and issued a $41.00 price objective on shares of Biohaven Pharmaceutical in a research report on Friday, May 8th. Finally, Wedbush raised their price objective on shares of Biohaven Pharmaceutical from $74.00 to $94.00 and gave the stock an “outperform” rating in a report on Thursday, June 18th. Two equities research analysts have rated the stock with a hold rating and eleven have given a buy rating to the stock. Biohaven Pharmaceutical presently has a consensus rating of “Buy” and an average target price of $76.91.
About Biohaven Pharmaceutical
Biohaven Pharmaceutical Holding Company Ltd., a clinical-stage biopharmaceutical company, develops late-stage products candidates targeting neurological diseases in the United States. Its clinical stage products include Rimegepant, a product that has completed phase III trials and is in long-term safety ongoing process for acute treatment and prevention of migraine; BHV-3500 that has completed phase I clinical trial for acute treatment and prevention of migraine; and Troriluzole that has completed II/III randomization phase and is ongoing extension trial for ataxias.
Recommended Story: Basic Economics creates winners and losers
Receive News & Ratings for Biohaven Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biohaven Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.